Trading Halt
Filed with ASX · · 2 pages · English
Summary by 6ix AI
Recce Pharmaceuticals Ltd has requested a trading halt for its securities pending the release of a significant announcement regarding clinical trial data. The halt will remain in effect until normal trading resumes or the announcement is made public, whichever comes first.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
On 6ix: 6ix.com/news/trading-halt-489
Recce Pharmaceuticals Ltd. on 6ix
Earlier from Recce Pharmaceuticals
- Pause in Trading
- Correction to Appendix 4C and Quarterly Activities Report
- Patient Dosing Complete in Phase II ABSSSI Trial of R327G
- Regulatory Approval for Registrational Phase 3 R327G Trial
- Australia Patent Granted for RECCE Anti-Infectives
Later from Recce Pharmaceuticals
- Positive Phase II Data from Clinical Trial of R327 Gel
- Recce Pharmaceuticals Reports Positive Data from Phase II Trial of RECCE® 327 Gel in Acute Bacterial Skin and Skin Structure Infections, Supporting Accelerated Commercialization Pathway
- Japan Patent Allowance for RECCE Anti-Infectives
- Recce Pharmaceuticals Granted Japanese Patent for RECCE® Anti-Infectives
- Key Opinion Leader Presentation
Follow Recce Pharmaceuticals into a list and get an email when it puts out news.
Follow Recce Pharmaceuticals